Genmab board members get restricted stock units after extraordinary meeting

Genmab A/S held an Extraordinary General Meeting on October 7, 2026, where shareholders approved the Board of Directors' proposal on remuneration of the Board for 2026, including share-based remuneration in the form of restricted stock units.¹

Following the vote, a total of 5,300 restricted stock units were granted to the members of the Board of Directors in accordance with Genmab A/S' Remuneration Policy.¹ Each unit carries specific terms: it is awarded cost-free and gives the holder a conditional right to receive one share in Genmab A/S with a nominal value of DKK 1.¹ The valuation was set at the time of grant, as the fair value of each restricted stock unit equals the closing market price of one Genmab A/S share on the date of grant, DKK 2,487.00.¹

Vesting is not immediate. The restricted stock units will vest on the first banking day of the month following a three-year period from the date of grant, subject to the terms of Genmab's Remuneration Policy and the applicable restricted stock unit program.¹

Genmab describes itself as a company focused on antibody medicines, and according to the filing, for over 25 years its team has advanced a range of antibody-based therapeutic formats including bispecific antibodies, antibody-drug conjugates, immune-modulating antibodies and other next-generation modalities, with eight approved antibody medicines and a late-stage clinical pipeline that includes wholly owned programs.¹ The company was established in 1999 and is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific.¹

The filing was signed by Anthony Pagano, Executive Vice President and Chief Financial Officer, dated October 7, 2026.